Heterocyclic amides of formula (1) ##STR00001## wherein: m is 0, 1 or 2; n is 0, 1 or 2; B is phenyl or heterocyclyl; R.sup.1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R.sup.2 and R.sup.3 are independently selected from, for example, C.sub.5-7cycloalkyl, cyano(C.sub.1-4)alkyl, C.sub.1-4alkyl (optionally substituted with 1 or 2 R.sup.8 groups), --OR.sup.8 and R.sup.8; R.sup.4 is independently selected from for example hydrogen, halo, nitro, cyano, hydroxy, C.sub.1-4alkyl, and C.sub.1-4alkanoyl; R.sup.8 is selected from for example hydroxy, heterocyclyl, aryl, --COCOOR.sup.9, --C(O)N(R.sup.9)(R.sup.10), (R.sup.9)(R.sup.10)N-- and --COOR.sup.9; R.sup.9 and R.sup.10 are selected from for example hydrogen, hydroxy, C.sub.1-4alkyl (optionally substituted by 1 or 2 R.sup.13); R.sup.13 is selected from for example, hydroxy, C.sub.1-4alkoxy, heterocyclyl and C.sub.1-4alkanoyl; R.sup.14 is selected from for example, hydrogen, halo, C.sub.1-4alkyl, C.sub.5-7cycloalkyl, C.sub.1-4alkoxy, cyano, cyano(C.sub.1-4)alkyl, --COR.sup.3, (R.sup.2)(R.sup.3)NCO--, and (R.sup.2)(R.sup.3)NSO.sub.2--; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.